RECOGNIZING MOVEMENT DISORDER EMERGENCIES – A PRACTICAL REVIEW FOR NON-NEUROLOGIST

Haris Hakeem, Memoona Nasir, Muhammad Farhan Khan, Nabeel Muzaffar Syed, Haris Majid Rajput, Arsalan Ahmad, Muhammad Athar Javed, Danish Ejaz Bhatti

Abstract


Neurology still remains one of the most underserved specialties of medicine in Pakistan with roughly one neurologist per million people. Movement disorders (MD) are neurological problems that interfere with patient’s motor abilities and diagnosis is typically clinical. In this review, we describe a practical approach to common MD emergencies that may be encountered by a non-neurologist physician, emphasizing on formulating a working diagnosis and their immediate management. Movement disorder emergencies can be classified based on MD phenomenology and we will provide a brief overview of dystonia including acute dystonic reaction, PAID syndrome and dystonic storm; chorea, myoclonus including serotonin syndrome and startle disease; and rigidity including neuroleptic malignant syndrome and malignant hyperthermia.

Keywords: Movement Disorders; Emergency; Neurology; Dystonia; Tardive; Serotonin Syndrome; Neuroleptic Malignant Syndrome

Full Text:

Untitled PDF

References


Moulin T, Sablot D, Vidry E, Belahsen F, Berger E, Lemounaud P, et al. Impact of emergency room neurologists on patient management and outcome. Eur Neurol 2003;50(4):207–14.

Awan T, Ahmad A, Javed A, Wasay M, Babar Khan M, Awan H. Neurological health profile in pakistan–A health systems based needs assessment. Pak J Neurol Sci 2016;11(4):43–56.

Abdo WF, Van De Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol 2010;6(1):29–37.

Munhoz RP, Scorr LM, Factor SA. Movement disorders emergencies. Curr Opin Neurol 2015;28(4):406–12.

Park HW, Kwak JR, Lee JS. Clinical characteristics of acute drug-induced dystonia in pediatric patients. Clin Exp Emerg Med 2017;4(3):133–7.

Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997;16(3):180–204.

Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984;2(3):541–54.

Bendigo V. The management of acute dystonic reactions. Aust Presc. 2001;24(1):19–20.

Kapoor D, Singla D, Singh J, Jindal R. Paroxysmal autonomic instability with dystonia (PAID) syndrome following cardiac arrest. Singapore Med J 2014;55(8):e123–5.

Baguley IJ. Autonomic complications following central nervous system injury. Semin Neurol 2008;28(5):716–25.

Lee S, Jun GW, Jeon SB, Kim CJ, Kim JH. Paroxysmal sympathetic hyperactivity in brainstem-compressing huge benign tumors: clinical experiences and literature review. Springerplus 2016;5:340.

Ruiz‐Lopez M, Fasano A. Rethinking status dystonicus. Mov Disord 2017;32(12):1667–76.

Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord 2017;4:10.

Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics 2014;11(1):208–12.

Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep 2017;17(1):6.

Patankar AP. Hemi-chorea: an unusual presentation of brainstem glioma. Br J Neurosurg 2013;27(2):256–8.

Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J 2004;80(949):642–9.

Poston KL, Frucht SJ. Movement disorder emergencies. J Neurol 2008;255(Suppl 4):2–13.

Deardorff OG, Khan T, Kulkarni G, Doisy R, Loehr C. Serotonin syndrome: Prophylactic treatment with cyproheptadine. Prim Care Companion CNS Disord 2016;18(4).

James J. Lamberg, Vitaly N. Gordin. Serotonin Syndrome in a Patient with Chronic Pain Polypharmacy. Pain Med 2014;15(8):1429–31.

Hiraga A, Kuwabara S. Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis. Intern Med 2017;56(21):2865–9.

Kallem VR, Kiran S, Murki SR. Nose-tapping Test in Hyperekplexia. Indian Pediatr 2018;55(5):432.

Tse L, M Barr A, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 2015;13(3):395–406.

Strawn JR, Keck Jr, MD PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870–6.

Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 2015;15(1):45–62.

Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 2016;24(1):97–103.

Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome: Focus on treatment and rechallenge. Ann Pharmacother 2016;50(11):973–81.

Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl) 2015;232(1):1–5.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015;10:93.

Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 2014;10:355–62.

Smith JL, Tranovich MA, Ebraheim NA. A comprehensive review of malignant hyperthermia: Preventing further fatalities in orthopedic surgery. J Orthop 2018;15(2):578–80.

Burns A, Gallagley A, Byrne J. Delirium. J Neurol Neurosurg Psychiatry 2004;75(3):362–7.

Kalabalik J, Brunetti L, El-Srougy R. Intensive care unit delirium: a review of the literature. J Pharm Pract 2014;27(2):195–207.

Vardy ER, Teodorczuk A, Yarnall AJ. Review of delirium in patients with Parkinson’s disease. J Neurol 2015;262(11):2401–10.

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42–80.


Refbacks

  • There are currently no refbacks.


Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]